Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Geron’s Testing of Imetelstat for Myelofibrosis to Continue

March 20 (Bloomberg) -- Geron Corp., ordered this month to stop testing its experimental drug in blood disorders, received permission from U.S. regulators to continue a trial of the compound for a bone marrow disorder.

No new patients will be enrolled in the study of imetelstat for myelofibrosis because of the partial clinical hold by the U.S. Food and Drug Administration, the Menlo Park, California-based company said in a statement today. Current participants must show a clinical benefit to stay in the trial, Geron said.

Geron, which has no products on the market, plunged 62 percent on March 12 after the FDA halted trials of imetelstat in essential thrombocythemia, polycythemia vera and multiple myeloma. The regulator stopped the tests because of the possibility of liver damage, Geron said.

To contact the reporter on this story: Caroline Chen in New York at cchen509@bloomberg.net

To contact the editors responsible for this story: Reg Gale at rgale5@bloomberg.net Bruce Rule, Robert Valpuesta

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.